← All organizations

Roche

For profitContributed to NMEWebsite ↗

Also known as: Carmot Therapeutics, Inc., a Member of the Roche Group | CHD de Vendee LA ROCHE SUR YON France | CHD La Roche sur Yon | CHD of La Roche/Yon | CHD Vendee | CHD VENDEE - La Roche sur Yon | F. Hoffmann-La Roche | F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute | Genentech, Inc. | GENENTECH INC | HLR | Hofffmann-La Roche | HOFFMAN-LA ROCHE | Hoffmann-LaRoche | Hoffmann-La Roche | HOFFMANN LA ROCHE | HOFFMANN-LA ROCHE | Hoffmann-La Roche, 973-235-5000 | Hoffmann-La Roche Inc. | nv Roche sa | ROCHE | Roche, Austria | Roche BV Netherlands | Roche Chugai | Roche, Copenhagen | Roche Diagnostics | Roche Diagnostics International AG | Roche Farma, S.A | Roche for trial and Saquinavir,and Abbott for Kaletra | Roche Foundation of Anemia Research (RoFAR, Switzerland) | Roche-Genentech | Roche/Genentech Inc. | Roche/Genetech | Roche Global Development | Roche (Grenzach-Wyhlen, Germany) | Roche Korea co.,Ltd. | Roche Molecular Systems, Inc | ROCHE PALO | Roche Pharma AG | Roche Pharma AG, 79639 Grenazch Wyhlen, Germany | Roche Pharma, Italy | Roche Products (India) Pvt. Ltd. | Roche Products Pty Limited | Roche - Prof. Dr. Jens Huober et al. | Roche S.p.a | Roche SpA | Roche Therapeutics Ltd

Highest phase reached

Phase 4

First clinical trial

Jul 1, 1992

First marketed drug

Jul 15, 1941

First NDA

Jul 15, 1941

Last known activity

Mar 31, 2026

Timeline

1890s

  1. Jan 1, 1896

    Roche— Founded

1970s

  1. Jan 1, 1975

    Medi-Physics— Acquired

1980s

  1. Jan 1, 1982

    Biomedical Reference Laboratories— Acquired

  2. Dec 21, 1984

    lidocaine— Marketing Organization

1990s

  1. Jan 1, 1994

    Syntex— Acquired

  2. Jan 1, 1997

    Boehringer-Mannheim— Acquired

  3. Apr 23, 1999

    orlistat— NDA Organization

2000s

  1. Jan 1, 2005

    Glycart— Acquired

  2. Jan 1, 2007

    454 Life Sciences— Acquired

  3. Jan 1, 2007

    Nimblegen— Acquired

  4. Jan 1, 2007

    Spring BioScience Corp— Acquired

  5. Jan 1, 2007

    Therapeutic Human Polyclonals— Acquired

  6. Jan 1, 2008

    Memory Pharmaceuticals— Acquired

  7. Jan 1, 2008

    Piramed— Acquired

  8. Jan 1, 2009

    GenentechGenentech— Acquired

  9. Jan 1, 2009

    Ventana Medical Systems— Acquired

2010s

  1. Jan 1, 2010

    BioImagene— Acquired

  2. Jan 1, 2010

    Marcadia Biotech— Acquired

  3. Jan 1, 2010

    Medingo Medical Solutions— Acquired

  4. Jan 1, 2011

    Anadys Pharmaceuticals— Acquired

  5. Jan 1, 2011

    MTM Laboratories AG— Acquired

  6. Jan 1, 2011

    PVT Probenvertiltechnik GmbH— Acquired

  7. Jan 1, 2014

    Ariosa Diagnostics— Acquired

  8. Jan 1, 2014

    Bina Technologies— Acquired

  9. Jan 1, 2014

    Chugai— Acquired

  10. Jan 1, 2014

    Constitution Medical Inc— Acquired

  11. Jan 1, 2014

    Genia Technologies, Inc— Acquired

  12. Jan 1, 2014

    InterMune— Acquired

  13. Jan 1, 2014

    Iquum— Acquired

  14. Jan 1, 2014

    Seragon Pharmaceuticals— Acquired

  15. Aug 4, 2014

    Santaris Pharma A/S— Acquired

  16. Jan 1, 2015

    Adheron Therapeutics— Acquired

  17. Jan 1, 2015

    Foundation Medicine— Acquired

  18. Jan 1, 2015

    GeneWeave— Acquired

  19. Jan 1, 2015

    Kapa Biosystems— Acquired

  20. Jan 1, 2015

    Trophos— Acquired

  21. Dec 1, 2016

    Tensha Therapeutics— Acquired

  22. Jan 1, 2017

    Forsight Vision4— Acquired

  23. Feb 1, 2018

    Ignyta, Inc.— Acquired

  24. Feb 14, 2019

    Spark Therapeutics— Acquired

  25. Nov 15, 2019

    Promedior, Inc.— Acquired

2020s

  1. Aug 7, 2020

    risdiplam— NDA Secondary Org

  2. Sep 22, 2020

    Inflazome— Acquired

  3. Mar 15, 2021

    GenMark Diagnostics— Acquired

  4. Dec 4, 2023

    Carmot Therapeutics, Inc.— Acquired

  5. Nov 26, 2024

    Poseida Therapeutics, Inc.— Acquired

  6. Oct 1, 2025

    89bio Ltd.— Acquired

Drugs by trial phase (898 distinct, 3945 trials)

Indications

Approved for

Studied for

Marketed drugs (102)

Subsidiaries (43 direct, 46 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Basel, CH Jan 1, 1896
First NDA
Jul 15, 1941
Last known activity
Mar 31, 2026

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy
  • Accelerated approval